The companyβs revenue from operations in the reporting period increased 15% year-on-year (YoY) to Rs 5,086 crore as against Rs 4,418 crore in the last year quarter.
Segment-wise, revenue for the healthcare services grew 15% YoY to Rs 2,637 crore and EBITDA for the business also rose 15% to Rs 622 crore. PAT for the segment came in at Rs 328 crore, which is a growth of 24% YoY.
Also Read: SpiceJet Q1 Results
Below is a brief note from various brokerage firms on the Q1 update:
JP Morgan: Overweight| Target price: Rs 6,800
JP Morgan maintained its overweight rating on the stock with a target price of Rs 6800.Q1 was in line with estimates. A strong uptick in occupancy was seen.Weak ARPOB growth, Apollo 24/7’s GMV grew moderate and margin declines were seen as key negatives while healthy revenue growth across segments and a strong improvement in occupancy were key positives.
UBS: Buy| Target price: Rs 7,500
UBS has maintained a buy rating on Apollo Hospitals with a target price of Rs 7500.
The global brokerage firm felt that Q1FY25 was a well rounded performance with revenue and EBITDA growing at 15% and 33% respectively as the healthcare revenue grew due to improved occupancy and outpatient volume.
Citi: Buy| Target price: RS 7,670
Citi has maintained a buy rating on the stock with a target price of Rs 7670.
Citi stated that Q1 was a healthy and in-line quarter as the hospitals growth was largely driven by IP volumes though ARPOB growth was a bit muted. Apollo Health and Lifestyle witnessed a margin improvement in diagnostics and primary care. In Healthco, offline pharmacy distribution margins were slightly subdued.
Also read: Mining stocks like NMDC, Tata Steel fall up to 5% on SC royalty order
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
Source link
